TY - JOUR
T1 - New Oral Anticoagulants. Their Role in Stroke Prevention in High-Risk Patients with Atrial Fibrillation
AU - Ferns, Sunita J.
AU - Naccarelli, Gerald V.
PY - 2015/7/1
Y1 - 2015/7/1
N2 - Based on efficacy, safety, and ease of use, novel oral anticoagulants will likely replace VKAs for many if not most patients with atrial fibrillation. Novel anticoagulants have a lower rate of intracranial hemorrhage compared with vitamin K antagonists. The incidence of other life-threatening bleeds is similar if not lower. Dose adjustments need to be made based on renal function and advanced age. There is at present a need for an antidote for these new drugs.
AB - Based on efficacy, safety, and ease of use, novel oral anticoagulants will likely replace VKAs for many if not most patients with atrial fibrillation. Novel anticoagulants have a lower rate of intracranial hemorrhage compared with vitamin K antagonists. The incidence of other life-threatening bleeds is similar if not lower. Dose adjustments need to be made based on renal function and advanced age. There is at present a need for an antidote for these new drugs.
UR - https://www.scopus.com/pages/publications/84931575182
UR - https://www.scopus.com/pages/publications/84931575182#tab=citedBy
U2 - 10.1016/j.mcna.2015.02.006
DO - 10.1016/j.mcna.2015.02.006
M3 - Review article
C2 - 26042881
AN - SCOPUS:84931575182
SN - 0025-7125
VL - 99
SP - 759
EP - 780
JO - Medical Clinics of North America
JF - Medical Clinics of North America
IS - 4
ER -